Preparation method and application of an immunosensor of oxygen vacancy-rich zinc-manganese bimetallic oxide
Through an electrochemiluminescence immunosensor with oxygen-enriched vacancies zinc-manganese bimetallic oxide and silica and polydopamine composite, the immediacy and conductivity problems in cardiac troponin I detection are solved, achieving high sensitivity and low detection Limited detection effect.
Patent Information
- Application Number
- CN202211134793.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-19
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing cardiac troponin I detection methods have problems such as difficulty in real-time and rapid detection, radioactive contamination and complex operation, and the poor conductivity of zinc manganate affects the detection efficiency.
Electrochemiluminescence immunosensors using oxygen-rich vacancies zinc-manganese bimetallic oxides and silica and polydopamine composite materials to regulate the electronic structure and enhance the conductivity through oxygen vacancies, and combine SiO2@PDA as a marker to build a high-sensitivity electricity Chemiluminescence detection system.
Fast, sensitive and specific detection of cardiac troponin I, with a wide linear range, low detection limit, short response time, good stability and reproducibility, and can be within the range of 0.02 pg/mL ~ 200 ng/mL Accurate detection.
Abstract
Description
Technical Field
[0001] The present invention belongs to a preparation method and application of an immunosensor of zinc-manganese bimetallic oxide rich in oxygen vacancies. Specifically, a composite material of zinc-manganese bimetallic oxide with oxygen vacancies and luminol is used as a base material, and a composite material of silicon dioxide and polydopamine is used as a marker to label a second antibody, thereby preparing an immunosensor of zinc-manganese bimetallic oxide rich in oxygen vacancies, belonging to the fields of new functional nanomaterials, immunoassay and biosensor detection technology. Background Art
[0002] Acute myocardial infarction is the main cause of death from cardiovascular diseases, so early diagnosis of acute myocardial infarction is of great significance for the treatment of irreversible damage caused by myocardial infarction. Cardiac troponin I is the main biomarker for diagnosing myocardial infarction. Cardiac troponin I exists in trace amounts in the normal human body, but when myocardial infarction occurs, myocardial cell damage causes myocardial troponin I to be released into the blood, and myocardial troponin I will rise sharply, reaching a peak in about 24 hours, and then falling to normal levels after 7-10 days. The extent of the increase in cardiac troponin I is related to the degree of myocardial cell necrosis to a certain extent. If the patient's blood cardiac troponin I is abnormally elevated, it means the occurrence of myocardial damage or necrosis. Therefore, the detection of cardiac troponin I content is of great significance for the occurrence, prognosis and observation of therapeutic effects of acute myocardial infarction.
[0003] Transition metal oxides have attractive catalytic activity, high abundance, physicochemical stability and low toxicity. In recent years, they have attracted widespread attention in the fields of electrocatalysis, energy materials and batteries. Zinc manganate ZMO, as a spinel transition metal oxide, has the characteristics of stable physicochemical properties, low price, low oxidation potential, low toxicity, low cost and environmental friendliness. However, zinc manganate has poor conductivity in nature and large volume changes, which leads to slow electron diffusion, which has an extremely adverse effect on the sensitive determination of cardiac troponin I. In order to enhance the conductivity of zinc manganate, we introduced oxygen vacancies on the surface of zinc manganate. The formation of oxygen vacancies leads to vacant oxygen atoms, which in turn affects the rearrangement of surrounding electrons, which is conducive to regulating electronic conductivity, increasing electrochemical active sites, accelerating charge diffusion, and thus significantly promoting the intensity of electrochemiluminescence ECL. At the same time, mesoporous silica SiO 2Nanoparticles have the advantages of large area, adjustable pore size, external surface chemical properties and inherent biocompatibility. The main characteristics of immunosensors prepared by silica are high specific surface area, mechanical stability, chemical inertness and excellent biocompatibility. Polydopamine PDA, formed by the oxidative polymerization of dopamine, is a melanin-like biopolymer in many organisms and contains a large number of hydroxyl and amino functional groups. Due to the interaction between these functional groups, polydopamine is easily functionalized. On this basis, a composite material of silica and polydopamine was synthesized to improve biocompatibility and surface area. In addition, the active quinones on the surface of the composite film of silica and polydopamine can be used to further immobilize antibodies. At the same time, polydopamine is considered to be an ECL quencher, and other catechol derivatives can quench the ECL intensity through photoinduced electron transfer.
[0004] At present, the methods used to detect cardiac troponin I antigen are mainly radioimmunoassay, enzyme-linked immunosorbent assay and fluorescent immunoassay, but these methods have the disadvantages of not being able to detect immediately and quickly, radioactive pollution and complicated operation, while the electrochemiluminescence method can overcome these disadvantages. Electrochemiluminescence is a redox reaction-induced luminescence process, in which the reactants produce an excited state through electrochemical reactions on the electrode surface, and emit light in the process of returning from the excited state to the ground state. The immunosensor constructed based on the specific recognition of antigens and antibodies has a simple preparation process, high sensitivity, low detection limit, and fast response speed, and can detect cardiac troponin I quickly and sensitively. Summary of the invention
[0005] The invention provides a method for preparing an immunosensor of oxygen vacancy-rich zinc-manganese bimetallic oxide, which realizes accurate and sensitive detection of cardiac troponin I.
[0006] One of the purposes of the present invention is to provide a method for preparing an immunosensor of an oxygen vacancy-rich zinc-manganese bimetallic oxide.
[0007] The second purpose of the present invention is to apply the prepared oxygen vacancy-rich zinc-manganese bimetallic oxide electrochemiluminescence immunosensor to the detection of cardiac troponin I.
[0008] The technical solution of the present invention is as follows:
[0009] 1. A method for preparing an immunosensor of oxygen vacancy-rich zinc-manganese bimetallic oxide, comprising the following steps:
[0010] (1) Polish a glassy carbon electrode with a diameter of 3.0 to 5.0 mm into a mirror surface using alumina polishing powder and clean it by ultrasonic cleaning in anhydrous ethanol;
[0011] (2) Take 5.0 μL of 0.5 ~ 5.0 mg / mL Lu@Ov-ZMO dispersion and drop it onto the electrode surface. Let it dry naturally at room temperature. Rinse the electrode surface with ultrapure water and let it dry at room temperature.
[0012] (3) Continue to add 6.0 µL of 5.0 ~ 15.0 µg / mL cardiac troponin I antibody to the electrode surface and dry in a 4°C refrigerator;
[0013] (4) Continue to add 3.0 µL of 1.0 ~ 2.0 wt% bovine serum albumin solution to the electrode surface to block the nonspecific active sites on the electrode surface, rinse the electrode surface with pH = 6.98 phosphate buffer, and dry it in a refrigerator at 4°C;
[0014] (5) Add 6.0 µL of a series of different concentrations of cardiac troponin I antigen solutions ranging from 0.02 pg / mL to 200 ng / mL, pH = 6.98 phosphate buffer to rinse the electrode surface and dry in a 4°C refrigerator;
[0015] (6) Add 6.0 µL of 3.0 ~ 8.0 mg / mL detection antibody incubated with SiO 2 @PDA-Ab 2 The dispersed droplets were applied to the electrode surface, placed in a 4°C refrigerator for 30 to 40 min, rinsed with a phosphate buffer solution with pH = 6.98, and placed in a 4°C refrigerator to dry, thereby obtaining an oxygen vacancy-rich zinc-manganese bimetallic oxide immunosensor.
[0016] 2. Preparation of Lu@Ov-ZMO dispersion, including the following steps:
[0017] (1) Preparation of Ov-ZMO
[0018] 1.05 g polyvinyl pyrrolidone, 2.17 g zinc acetate dihydrate and 4.95 g manganese acetate tetrahydrate were dispersed in 100 mL of a 1:1 mixed solution of anhydrous ethanol and dimethylformamide to form solution A; 6.0-6.5 g isonicotinic acid was dissolved in 60 mL of a 1:1 mixed solution of anhydrous ethanol and dimethylformamide to form solution B; then solution A was added to solution B and heated to 140°C for 24 h, cooled and centrifuged, and the precipitate was washed three times with anhydrous ethanol and dimethylformamide in a volume ratio of 1:1, dried in vacuo at 80°C, and placed in a tube furnace at 2°C min -1 The temperature was raised to 500-700℃ at a rate of 2℃·min and maintained for 2 h. After cooling, the temperature was continued to rise at 2℃·min in a nitrogen flow. -1 The temperature was raised to 700 °C at a rate of 2 h to obtain Ov-ZMO.
[0019] (2) Preparation of Lu@Ov-ZMO
[0020] Dissolve 5.0 mL of 5.0 ~ 10.0 mmol / L luminol solution in 10 mL of 0.1 mol / L sodium hydroxide solution, add 20 mL of 5.0 ~ 10.0 mg / mL Ov-ZMO solution, stir at room temperature for 6 h, centrifuge at 7000 r / min for 3 min, and dry the precipitate at 50 °C for 2 h to obtain Lu@Ov-ZMO;
[0021] 0.5 ~ 5.0 mg Lu@Ov-ZMO was ultrasonically dispersed in 1.0 mL ultrapure water to prepare Lu@Ov-ZMO dispersion for later use.
[0022] 3. SiO 2 @PDA-Ab 2 The preparation of the dispersion comprises the following steps:
[0023] (1) SiO 2 Preparation
[0024] 1.5 mL of n-pentanol, 30 mL of cyclohexane and 2.7 mL of 10-15 mmol / L tetraethyl chlorosilicate were stirred continuously to form solution A; 1.5-2.0 g of hexadecyltrimethylammonium bromide and 0.6 g of urea were added to 30 mL of ultrapure water to form solution B; solution B was quickly added to solution A and stirred for 0.5 h, and the mixture was transferred to a 50 mL autoclave, heated at 120 °C for 4 h, cooled to room temperature, and then centrifuged and washed three times with acetone and ultrapure water in sequence, and the precipitate was collected, dried in vacuo, and heated at 1 °C min -1 The temperature was raised to 550℃ and maintained for 6 to 8 h to obtain SiO 2 ;
[0025] (2) SiO 2 Preparation of @PDA
[0026] Dissolve 0.05-0.10 g dopamine in 30 mL 10 mmol / L tris(hydroxymethyl)aminomethane hydrochloride solution, and add 0.05-0.10 g SiO 2 The mixture was stirred continuously at room temperature for 20 h, centrifuged at 7000 r / min for 5 min, and dried under vacuum at 50 °C to obtain SiO 2 @PDA;
[0027] (3) Detection of antibody incubation SiO 2 @PDA-Ab 2 Preparation of dispersion
[0028] Add 1.0 ~ 3.0 mL of 2.0 mg / mL SiO 2 @PDA solution was added to 1.0 mL of 10 μg / mL detection antibody Ab 2 The solution was incubated in a 4°C constant temperature oscillating box for 12 h; after centrifugation and washing, it was redispersed in 1.0 to 3.0 mL of pH = 6.98 phosphate buffer solution to prepare the detection antibody incubation SiO 2 @PDA-Ab 2 The solution was stored at 4°C for future use.
[0029] 4. Detection of cardiac troponin I, the steps are as follows:
[0030] (1) The three-electrode system of the electrochemical workstation was used for testing. The Ag / AgCl electrode was used as the reference electrode, the platinum wire electrode was used as the counter electrode, and the prepared electrochemiluminescence immunosensor was used as the working electrode. The electrochemical workstation and the chemiluminescence detector were connected together. The high voltage of the photomultiplier tube was set to 600 V, the cyclic voltammetry scan range was 0.2 ~ 0.8 V, and the scan rate was 0.1 V / s.
[0031] (2) In 10 mL, pH = 6.98 phosphate buffer solution, the electrochemiluminescence signal intensity generated by the electrochemiluminescence system for different concentrations of the antigen to be tested was detected, and a working curve was drawn;
[0032] (3) The sample solution is used instead of the cardiac troponin I antigen solution for testing.
[0033] The prepared electrochemiluminescent immunosensor has a linear detection range of 0.02 pg / mL to 200 ng / mL and a detection limit of 6.6 fg / mL.
[0034] The chemical reagents required for material synthesis were purchased from local reagent stores without further processing.
[0035] Beneficial results of the present invention
[0036] (1) The present invention successfully synthesized an Ov-ZMO material with a certain loading capacity. The material has a simple preparation method and a large specific surface area, and can load more primary antibodies and luminescent material luminol. The introduction of oxygen vacancies can adjust the electronic structure of ZMO, which is beneficial to enhance the electronic conductivity, thereby solving the problem of low luminescence efficiency of the pure luminol system.
[0037] (2) The present invention utilizes SiO 2@PDA is used as a secondary antibody marker. Mesoporous silica nanoparticles have the characteristics of large surface area, adjustable pore size, external surface chemistry and inherent biocompatibility. The main characteristics of silica in the manufacture of immunosensors are high specific surface area, mechanical stability, chemical inertness and excellent biocompatibility. Polydopamine contains a large number of hydroxyl and amino functional groups. Due to the presence of these functional groups, polydopamine is easy to functionalize. On this basis, SiO 2 @PDA improves its biocompatibility and surface area. Polydopamine can quench the ECL intensity through photoinduced electron transfer to construct a quenching electrochemiluminescence immunosensor.
[0038] The electrochemiluminescent immunosensor of the present invention achieves the purpose of accurate quantitative detection of cardiac troponin I antigen, has a short response time, a wide linear range, a low detection limit, good stability and reproducibility, and can achieve simple, fast, highly sensitive and specific detection. The linear range of the detection of cardiac troponin I of the present invention is 0.02 pg / mL to 200 ng / mL, and the detection limit is 6.6 fg / mL. DETAILED DESCRIPTION
[0039] The present invention is now further described by specific embodiments, but is not limited thereto.
[0040] Example 1 A method for preparing an immunosensor of oxygen vacancy-rich zinc-manganese bimetallic oxide comprises the following steps:
[0041] (1) Polish a glassy carbon electrode with a diameter of 3.0 mm into a mirror surface using alumina polishing powder and clean it by ultrasonic cleaning in anhydrous ethanol;
[0042] (2) Take 5.0 μL of 0.5 mg / mL Lu@Ov-ZMO dispersion and drop it onto the electrode surface. Let it dry naturally at room temperature. Rinse the electrode surface with ultrapure water and let it dry at room temperature.
[0043] (3) Continue to add 6.0 µL, 5.0 µg / mL cardiac troponin I antibody to the electrode surface and dry in a 4°C refrigerator;
[0044] (4) Continue to add 3.0 μL of 1.0 wt% bovine serum albumin solution to the electrode surface to block the nonspecific active sites on the electrode surface, rinse the electrode surface with pH = 6.98 phosphate buffer, and dry it in a refrigerator at 4°C;
[0045] (5) Add 6.0 µL of a series of different concentrations of cardiac troponin I antigen solutions ranging from 0.02 pg / mL to 200 ng / mL, pH = 6.98 phosphate buffer to rinse the electrode surface and dry in a 4°C refrigerator;
[0046] (6) Add 6.0 µL of 3.0 mg / mL detection antibody incubated with SiO 2 @PDA-Ab 2 The dispersed droplets were applied to the electrode surface, placed in a 4°C refrigerator for 30 min, rinsed with a phosphate buffer solution with pH = 6.98, and placed in a 4°C refrigerator to dry, thereby obtaining an oxygen vacancy-rich zinc-manganese bimetallic oxide immunosensor.
[0047] Example 2 A method for preparing an immunosensor of oxygen vacancy-rich zinc-manganese bimetallic oxide comprises the following steps:
[0048] (1) Polish a glassy carbon electrode with a diameter of 4.0 mm into a mirror surface using alumina polishing powder and clean it by ultrasonic cleaning in anhydrous ethanol;
[0049] (2) Take 5.0 μL of 3.0 mg / mL Lu@Ov-ZMO dispersion and drop it onto the electrode surface. Let it dry naturally at room temperature. Rinse the electrode surface with ultrapure water and let it dry at room temperature.
[0050] (3) Continue to add 6.0 µL, 10.0 µg / mL cardiac troponin I antibody to the electrode surface and dry in a 4°C refrigerator;
[0051] (4) Continue to add 3.0 μL of 1.5 wt% bovine serum albumin solution to the electrode surface to block the nonspecific active sites on the electrode surface, rinse the electrode surface with pH = 6.98 phosphate buffer, and dry it in a refrigerator at 4°C;
[0052] (5) Add 6.0 µL of a series of different concentrations of cardiac troponin I antigen solutions ranging from 0.02 pg / mL to 200 ng / mL, pH = 6.98 phosphate buffer to rinse the electrode surface and dry in a 4°C refrigerator;
[0053] (6) Add 6.0 µL of 5.0 mg / mL detection antibody incubated with SiO 2 @PDA-Ab 2 The dispersed droplets were applied to the electrode surface, placed in a 4°C refrigerator for 35 min, rinsed with a phosphate buffer solution with pH = 6.98, and placed in a 4°C refrigerator to dry, thereby obtaining an oxygen vacancy-rich zinc-manganese bimetallic oxide immunosensor.
[0054] Example 3. A method for preparing an immunosensor of oxygen vacancy-rich zinc-manganese bimetallic oxide, comprising the following steps:
[0055] (1) Polish a glassy carbon electrode with a diameter of 5.0 mm into a mirror surface using alumina polishing powder and clean it by ultrasonic cleaning in anhydrous ethanol;
[0056] (2) Take 5.0 μL of 5.0 mg / mL Lu@Ov-ZMO dispersion and drop it onto the electrode surface. Let it dry naturally at room temperature. Rinse the electrode surface with ultrapure water and let it dry at room temperature.
[0057] (3) Continue to add 6.0 µL, 15.0 µg / mL cardiac troponin I antibody to the electrode surface and dry in a 4°C refrigerator;
[0058] (4) Continue to add 3.0 μL of 2.0 wt% bovine serum albumin solution to the electrode surface to block the nonspecific active sites on the electrode surface, rinse the electrode surface with pH = 6.98 phosphate buffer, and dry it in a refrigerator at 4°C;
[0059] (5) Add 6.0 µL of a series of different concentrations of cardiac troponin I antigen solutions ranging from 0.02 pg / mL to 200 ng / mL, pH = 6.98 phosphate buffer to rinse the electrode surface and dry in a 4°C refrigerator;
[0060] (6) Add 6.0 µL, 8.0 mg / mL of detection antibody to the SiO 2 @PDA-Ab 2 The dispersed droplets were applied to the electrode surface, placed in a 4°C refrigerator for 40 min, rinsed with a phosphate buffer solution with pH = 6.98, and placed in a 4°C refrigerator to dry, thereby obtaining an oxygen vacancy-rich zinc-manganese bimetallic oxide immunosensor.
[0061] Example 4. Preparation of Lu@Ov-ZMO dispersion, comprising the following steps:
[0062] (1) Preparation of Ov-ZMO
[0063] 1.05 g polyvinyl pyrrolidone, 2.17 g zinc acetate dihydrate and 4.95 g manganese acetate tetrahydrate were dispersed in 100 mL of a mixed solution of anhydrous ethanol and dimethylformamide in a volume ratio of 1:1 to form solution A; 6.0 g isonicotinic acid was dissolved in 60 mL of a mixed solution of anhydrous ethanol and dimethylformamide in a volume ratio of 1:1 to form solution B; then solution A was added to solution B and heated to 140°C for 24 h, cooled and centrifuged, and the precipitate was washed three times with anhydrous ethanol and dimethylformamide in a volume ratio of 1:1, dried in vacuo at 80°C, and placed in a tube furnace at 2°C min -1 The temperature was raised to 500 °C at a rate of 2 °C·min and maintained for 2 h. After cooling, the temperature was further raised at 2 °C·min in a nitrogen flow. -1 The temperature was raised to 700℃ at a rate of 2 h to obtain Ov-ZMO.
[0064] (2) Preparation of Lu@Ov-ZMO
[0065] 5.0 mL of 5.0 mmol / L luminol solution was dissolved in 10 mL of 0.1 mol / L sodium hydroxide solution, and 20 mL of 5.0 mg / mL Ov-ZMO solution was added. The mixture was stirred at room temperature for 6 h, and then centrifuged at 7000 r / min for 3 min. The precipitate was dried at 50 °C for 2 h to obtain Lu@Ov-ZMO.
[0066] 0.5 mg Lu@Ov-ZMO was ultrasonically dispersed in 1.0 mL ultrapure water to prepare Lu@Ov-ZMO dispersion for later use.
[0067] Example 5. Preparation of Lu@Ov-ZMO dispersion, comprising the following steps:
[0068] (1) Preparation of Ov-ZMO
[0069] 1.05 g of polyvinyl pyrrolidone, 2.17 g of zinc acetate dihydrate and 4.95 g of manganese acetate tetrahydrate were dispersed in 100 mL of a mixed solution of anhydrous ethanol and dimethylformamide in a volume ratio of 1:1 to form solution A; 6.3 g of isonicotinic acid was dissolved in 60 mL of a mixed solution of anhydrous ethanol and dimethylformamide in a volume ratio of 1:1 to form solution B; then solution A was added to solution B and heated to 140°C for 24 h, cooled and centrifuged, and the precipitate was washed three times with anhydrous ethanol and dimethylformamide in a volume ratio of 1:1, and then placed in a tube furnace after vacuum drying at 80°C for 2°C min -1 The temperature was raised to 600 °C at a rate of 2 °C·min and maintained for 2 h. After cooling, the temperature was further raised in a nitrogen flow at a rate of 2 °C·min -1 The temperature was raised to 700℃ at a rate of 2 h to obtain Ov-ZMO.
[0070] (2) Preparation of Lu@Ov-ZMO
[0071] 5.0 mL of 8.0 mmol / L luminol solution was dissolved in 10 mL of 0.1 mol / L sodium hydroxide solution, and 20 mL of 8.0 mg / mL Ov-ZMO solution was added. The mixture was stirred at room temperature for 6 h, and then centrifuged at 7000 r / min for 3 min. The precipitate was dried at 50 °C for 2 h to obtain Lu@Ov-ZMO.
[0072] 3.0 mg Lu@Ov-ZMO was ultrasonically dispersed in 1.0 mL ultrapure water to prepare Lu@Ov-ZMO dispersion for later use.
[0073] Example 6. Preparation of Lu@Ov-ZMO dispersion, comprising the following steps:
[0074] (2) Preparation of Ov-ZMO
[0075] 1.05 g of polyvinyl pyrrolidone, 2.17 g of zinc acetate dihydrate and 4.95 g of manganese acetate tetrahydrate were dispersed in 100 mL of a mixed solution of anhydrous ethanol and dimethylformamide in a volume ratio of 1:1 to form solution A; 6.5 g of isonicotinic acid was dissolved in 60 mL of a mixed solution of anhydrous ethanol and dimethylformamide in a volume ratio of 1:1 to form solution B; then solution A was added to solution B and heated to 140°C for 24 h, cooled and centrifuged, and the precipitate was washed three times with anhydrous ethanol and dimethylformamide in a volume ratio of 1:1, dried in vacuo at 80°C, and placed in a tube furnace at 2°C min -1 The temperature was raised to 700℃ at a rate of 2℃·min and maintained for 2 h. After cooling, the temperature was further raised in a nitrogen flow at a rate of 2℃·min -1 The temperature was raised to 700℃ at a rate of 2 h to obtain Ov-ZMO.
[0076] (3) Preparation of Lu@Ov-ZMO
[0077] 5.0 mL of 10 mmol / L luminol solution was dissolved in 10 mL of 0.1 mol / L sodium hydroxide solution, and 20 mL of 10 mg / mL Ov-ZMO solution was added. The mixture was stirred at room temperature for 6 h, and then centrifuged at 7000 r / min for 3 min. The precipitate was dried at 50 °C for 2 h to obtain Lu@Ov-ZMO.
[0078] 5.0 mg Lu@Ov-ZMO was ultrasonically dispersed in 1.0 mL ultrapure water to prepare Lu@Ov-ZMO dispersion for later use.
[0079] Example 7. SiO 2 @PDA-Ab 2 The preparation of the dispersion comprises the following steps:
[0080] (1) SiO 2 Preparation
[0081] 1.5 mL of n-pentanol, 30 mL of cyclohexane and 2.7 mL of 10 mmol / L tetraethyl chlorosilicate were stirred continuously to form solution A; 1.5 g of hexadecyltrimethylammonium bromide and 0.6 g of urea were added to 30 mL of ultrapure water to form solution B; solution B was quickly added to solution A and stirred for 0.5 h, and the mixture was transferred to a 50 mL autoclave, heated at 120 °C for 4 h, cooled to room temperature, and then centrifuged and washed three times with acetone and ultrapure water in sequence, and the precipitate was collected, dried in vacuum, and heated at 1 °C min -1 The temperature was raised to 550℃ and maintained for 6 h to obtain SiO2 ;
[0082] (2) SiO 2 Preparation of @PDA
[0083] Dissolve 0.05 g dopamine in 30 mL 10 mmol / L tris(hydroxymethyl)aminomethane hydrochloride solution and add 0.05 g SiO 2 The mixture was stirred continuously at room temperature for 20 h, centrifuged at 7000 r / min for 5 min, and dried under vacuum at 50 °C to obtain SiO 2 @PDA;
[0084] (3) Detection of antibody incubation SiO 2 @PDA-Ab 2 Preparation of dispersion
[0085] 1.0 mL of 2.0 mg / mL SiO 2 @PDA solution was added to 1.0 mL of 10 μg / mL detection antibody Ab 2 The solution was incubated in a 4°C constant temperature oscillating box for 12 h; after centrifugation and washing, it was redispersed in 1.0 mL of pH = 6.98 phosphate buffer solution to prepare the detection antibody incubation medium SiO 2 @PDA-Ab 2 The solution was stored at 4°C for future use.
[0086] Example 8. SiO 2 @PDA-Ab 2 The preparation of the dispersion comprises the following steps:
[0087] (1) SiO 2 Preparation
[0088] 1.5 mL of n-pentanol, 30 mL of cyclohexane and 2.7 mL of 13 mmol / L tetraethyl chlorosilicate were stirred continuously to form solution A; 1.8 g of hexadecyltrimethylammonium bromide and 0.6 g of urea were added to 30 mL of ultrapure water to form solution B; solution B was quickly added to solution A and stirred for 0.5 h, and the mixture was transferred to a 50 mL autoclave, heated at 120 °C for 4 h, cooled to room temperature, and then centrifuged and washed three times with acetone and ultrapure water in sequence, and the precipitate was collected, dried in vacuum, and heated at 1 °C min -1 The temperature was raised to 550℃ and maintained for 7 h to obtain SiO 2 ;
[0089] (2) SiO 2 Preparation of @PDA
[0090] Dissolve 0.08 g dopamine in 30 mL 10 mmol / L tris(hydroxymethyl)aminomethane hydrochloride solution and add 0.08 g SiO 2 The mixture was stirred continuously at room temperature for 20 h, centrifuged at 7000 r / min for 5 min, and dried under vacuum at 50 °C to obtain SiO 2 @PDA;
[0091] (3) Detection of antibody incubation SiO 2 @PDA-Ab 2 Preparation of dispersion
[0092] Add 2.0 mL of 2.0 mg / mL SiO 2 @PDA solution was added to 1.0 mL of 10 μg / mL detection antibody Ab 2 The solution was incubated in a 4°C constant temperature oscillating box for 12 h; after centrifugation and washing, it was redispersed in 2.0 mL of pH = 6.98 phosphate buffer solution to prepare the detection antibody incubation medium SiO 2 @PDA-Ab 2 The solution was stored at 4°C for future use.
[0093] Example 9. SiO 2 @PDA-Ab 2 The preparation of the dispersion comprises the following steps:
[0094] (1) SiO 2 Preparation
[0095] 1.5 mL of n-pentanol, 30 mL of cyclohexane and 2.7 mL of 15 mmol / L tetraethyl chlorosilicate were stirred continuously to form solution A; 2.0 g of hexadecyltrimethylammonium bromide and 0.6 g of urea were added to 30 mL of ultrapure water to form solution B; solution B was quickly added to solution A and stirred for 0.5 h, and the mixture was transferred to a 50 mL autoclave, heated at 120 °C for 4 h, cooled to room temperature, and then centrifuged and washed three times with acetone and ultrapure water in sequence, and the precipitate was collected, dried in vacuum, and heated at 1 °C min -1 The temperature was raised to 550℃ and maintained for 8 h to obtain SiO 2 ;
[0096] (2) SiO 2 Preparation of @PDA
[0097] Dissolve 0.10 g dopamine in 30 mL 10 mmol / L tris(hydroxymethyl)aminomethane hydrochloride solution and add 0.10 g SiO 2The mixture was stirred continuously at room temperature for 20 h, centrifuged at 7000 r / min for 5 min, and dried under vacuum at 50 °C to obtain SiO 2 @PDA;
[0098] (3) Detection of antibody incubation SiO 2 @PDA-Ab 2 Preparation of dispersion
[0099] 3.0 mL of 2.0 mg / mL SiO 2 @PDA solution was added to 1.0 mL of 10 μg / mL detection antibody Ab 2 The solution was incubated in a 4°C constant temperature oscillating box for 12 h; after centrifugation and washing, it was redispersed in 3.0 mL of pH = 6.98 phosphate buffer solution to prepare the detection antibody incubation SiO 2 @PDA-Ab 2 The solution was stored at 4°C for future use.
[0100] Example 10. Detection of cardiac troponin I, the steps are as follows:
[0101] (1) The three-electrode system of the electrochemical workstation was used for testing. The Ag / AgCl electrode was used as the reference electrode, the platinum wire electrode was used as the counter electrode, and the prepared electrochemiluminescence immunosensor was used as the working electrode. The electrochemical workstation and the chemiluminescence detector were connected together. The high voltage of the photomultiplier tube was set to 600 V, the cyclic voltammetry scan range was 0.2 ~ 0.8 V, and the scan rate was 0.1 V / s.
[0102] (2) In 10 mL, pH = 6.98 phosphate buffer solution, the electrochemiluminescence signal intensity generated by the electrochemiluminescence system for different concentrations of the antigen to be tested was detected, and a working curve was drawn;
[0103] (3) The sample solution was used instead of the cardiac troponin I antigen solution for detection. The linear range of cardiac troponin I detection was found to be 0.02 pg / mL ~ 200 ng / mL, and the detection limit was 6.6 fg / mL.
Claims
1. A method for preparing an immunosensor of oxygen vacancy-rich zinc-manganese bimetallic oxide, characterized in that: The following steps are involved: (1) A glassy carbon electrode with a diameter of 3.0 to 5.0 mm was polished into a mirror surface with aluminum oxide polishing powder and ultrasonically cleaned in anhydrous ethanol; (2) Take 5.0 μL of 0.5-5.0 mg / mL Lu@Ov-ZMO dispersion and drop it onto the electrode surface, let it dry naturally at room temperature, rinse the electrode surface with ultrapure water, and let it dry at room temperature; (3) Continue to add 6.0 μL of 5.0-15.0 μg / mL cardiac troponin I antibody to the electrode surface and dry in a 4°C refrigerator; (4) 3.0 μL of 1.0-2.0 wt% bovine serum albumin solution was added dropwise to the electrode surface to block nonspecific active sites on the electrode surface, and the electrode surface was rinsed with pH 6.98 phosphate buffer and dried in a refrigerator at 4°C; (5) Add 6.0 μL of a series of different concentrations of cardiac troponin I antigen solutions ranging from 0.02 pg / mL to 200 ng / mL, pH = 6.98 phosphate buffer to rinse the electrode surface and dry in a 4°C refrigerator; (6) 6.0 μL, 3.0-8.0 mg / mL of detection antibody incubated SiO2@PDA-Ab2 dispersion was droplet-coated on the electrode surface, placed in a 4°C refrigerator for 30-40 min, rinsed with pH=6.98 phosphate buffer, and placed in a 4°C refrigerator to dry, thereby obtaining an oxygen vacancy-rich zinc-manganese bimetallic oxide immunosensor.
2. The method for preparing an oxygen vacancy-rich zinc-manganese bimetallic oxide immunosensor according to claim 1, wherein the Lu@Ov-ZMO dispersion is prepared by the following steps: (1) Preparation of Ov-ZMO 1.05 g of polyvinyl pyrrolidone, 2.17 g of zinc acetate dihydrate and 4.95 g of manganese acetate tetrahydrate were dispersed in 100 mL of a mixed solution of anhydrous ethanol and dimethylformamide in a volume ratio of 1:1 to form solution A; 6.0-6.5 g of isonicotinic acid was dissolved in 60 mL of a mixed solution of anhydrous ethanol and dimethylformamide in a volume ratio of 1:1 to form solution B; then solution A was added to solution B and heated to 140°C for 24 h, cooled and centrifuged, and the precipitate was washed three times with anhydrous ethanol and dimethylformamide in a volume ratio of 1:1, and then placed in a tube furnace after vacuum drying at 80°C for 2°C min -1 The temperature was raised to 500-700℃ at a rate of 2℃·min and maintained for 2h; after cooling, the temperature was continued to rise in a nitrogen flow at a rate of 2℃·min -1 The temperature was raised to 700 °C at a rate of 1.5 ℃ and maintained for 2 h to obtain Ov-ZMO; (2) Preparation of Lu@Ov-ZMO Dissolve 5.0 mL of 5.0-10.0 mmol / L luminol solution in 10 mL of 0.1 mol / L sodium hydroxide solution, add 20 mL of 5.0-10.0 mg / mL Ov-ZMO solution, stir at room temperature for 6 h, centrifuge at 7000 r / min for 3 min, and dry the precipitate at 50 ° C for 2 h to obtain Lu@Ov-ZMO; 0.5-5.0 mg Lu@Ov-ZMO was ultrasonically dispersed in 1.0 mL ultrapure water to prepare Lu@Ov-ZMO dispersion for later use.
3. The method for preparing an oxygen vacancy-rich zinc-manganese bimetallic oxide immunosensor according to claim 1, wherein the preparation of the detection antibody incubation product SiO2@PDA-Ab2 dispersion comprises the following steps: (1) Preparation of SiO2 1.5 mL of n-pentanol, 30 mL of cyclohexane and 2.7 mL of 10-15 mmol / L tetraethyl chlorosilicate were stirred continuously to form solution A; 1.5-2.0 g of hexadecyltrimethylammonium bromide and 0.6 g of urea were added to 30 mL of ultrapure water to form solution B; solution B was quickly added to solution A and stirred for 0.5 h, and the mixture was transferred to a 50 mL autoclave, heated at 120 °C for 4 h, cooled to room temperature, and then centrifuged and washed three times with acetone and ultrapure water in sequence, and the precipitate was collected, vacuum dried, and heated at 1 °C min -1 The temperature was raised to 550°C at a rate of 100°C and maintained for 6 to 8 hours to obtain SiO2; (2) Preparation of SiO2@PDA 0.05-0.10 g dopamine was dissolved in 30 mL 10 mmol / L tris(hydroxymethyl)aminomethane hydrochloride solution, 0.05-0.10 g SiO2 was added to the solution, and the mixture was stirred continuously for 20 h at room temperature, and then centrifuged at 7000 r / min for 5 min, and dried under vacuum at 50 °C to obtain SiO2@PDA. (3) Preparation of SiO2@PDA-Ab2 dispersion for antibody incubation Add 1.0-3.0 mL of 2.0 mg / mL SiO2@PDA solution to 1.0 mL of 10 μg / mL detection antibody Ab2 solution, and incubate in a constant temperature oscillating box at 4°C for 12 h; after centrifugal washing, redisperse in 1.0-3.0 mL of pH=6.98 phosphate buffer solution to obtain detection antibody incubation SiO2@PDA-Ab2 dispersion, and store at 4°C for later use.
4. A detection method for a sensor prepared by the preparation method according to claim 1, characterized in that: For the detection of cardiac troponin I, the detection steps are as follows: (1) The three-electrode system of the electrochemical workstation was used for testing, with the Ag / AgCl electrode as the reference electrode, the platinum wire electrode as the counter electrode, and the prepared electrochemiluminescent immunosensor as the working electrode. The electrochemical workstation and the chemiluminescence detector were connected together, the high voltage of the photomultiplier tube was set to 600 V, the cyclic voltammetry scanning range was 0.2-0.8 V, and the scanning rate was 0.1 V / s; (2) In 10 mL of phosphate buffer solution at pH = 6.98, the electrochemiluminescence signal intensity generated by the antigen at different concentrations is detected by an electrochemiluminescence system, and a working curve is drawn; (3) The sample solution to be tested is used instead of the cardiac troponin I antigen solution for testing.
Citation Information
Patent Citations
Oxygen-vacancy-rich z-mechanism bi2o3@CEO2 photocatalyst, and preparation method and use thereof
AU2020100758A4
Preparation method and application of nitrogen-sulfur-double-doped-graphene-oxide-labeled sandwich type immunosensor
CN109709188A
Method for preparing sandwich type electrochemical immunosensor of cardiac troponin
CN109709189A
Detection method of iron-based spinel for heavy metal ion electrochemical sensor
CN110441365A
Preparation method and application of NiCo2O4 electrochemiluminescence sensor based on oxygen-enriched vacancy
CN111766288A
